Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in: Diabetology & Metabolic Syndrome 1/2018

Open Access 01-12-2018 | Research

Antidiabetic efficacy of lactoferrin in type 2 diabetic pediatrics; controlling impact on PPAR-γ, SIRT-1, and TLR4 downstream signaling pathway

Authors: Waleed A. Mohamed, Mona F. Schaalan

Published in: Diabetology & Metabolic Syndrome | Issue 1/2018

Login to get access

Abstract

The current study aims to investigate the antidiabetic efficacy of camel milk-derived lactoferrin and potential involvement of PPAR-γ and SIRT-1 via TLR-4/NFκB signaling pathway in obese diabetic pediatric population. Sixty young obese patients with type 2 diabetes were selected from the Pediatric Endocrine Metabolic Unit, Cairo University and were randomly divided among two age and sex-matched groups so as to receive either standard therapy without lactoferrin in one arm or to be treated with oral lactoferrin capsules (250 mg/day, p.o) for 3 months in the other arm. Both groups were compared to 50 control healthy volunteers. Measurements of HbA1c, lipid profile, antioxidant capacity (SOD, Nrf2), proinflammatory interleukins; (IL-1β, IL-6, IL-18), Cyclin D-1, lipocalin-2, and PPAR-γ expression levels were done at the beginning and 3 months after daily consumption of lactoferrin. The mechanistic involvement of TLR4-SIRT-1-NFκB signaling cascade was also investigated. The antidiabetic efficacy of lactoferrin was confirmed by significant improvement of the baseline levels of HbA1c, BMI and lipid profile of the obese pediatric cohort, which is evidenced by increased PPAR-γ and SIRT-1 expression. Moreover, the anti-inflammatory effect was evident by the significant decrease in serum levels of IL-1β, IL-6, IL-18, TNF-α, lipocalin 2 in type 2 diabetic post-treatment group, which corresponded by decreased NFκB downstream signaling indicators. The antioxidant efficacy was evident by stimulated SOD levels and NrF2 expression; compared with the pre-treatment group (all at P ≤ 0.001). The consumption of high concentrations of lactoferrin explains its hypoglycemic efficacy and counts for its insulin-sensitizing, anti-inflammatory and immunomodulatory effects via TLR4-NFκB-SIRT-1 signaling cascade. Recommendations on regular intake of lactoferrin could ensure better glycemic control, compared to conventional antidiabetics alone.
Literature
1.
Golden SH, Sapir T. Methods for insulin delivery and glucose monitoring in diabetes: summary of a comparative effectiveness review. J Manag Care Pharm. 2012;18:1–17.
2.
Schreiver C, Jacoby U, Watzer B, Thomas A, Haffner D, Fischer D. Glycaemic variability in pediatric patients with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI): a cross-sectional cohort study. Clin Endocrinol. 2013;79:641–7.
3.
Ryba-Stanisławowska M, Rybarczyk-Kapturska K, Myśliwiec M, Myśliwska J. Elevated levels of serum IL-12 and IL-18 are associated with lower frequencies of CD4+ CD25highFOXP3+ regulatory T cells in young patients with type 1 diabetes. Inflammation. 2014;37:1513–20.CrossRefPubMedPubMedCentral
4.
Van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev. 2011;91:79–118.CrossRefPubMed
5.
Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol. 2009;5:219–26.CrossRefPubMed
6.
Wolter TR, Wong R, Sarkar SA, Zipris D. DNA microarray analysis for the identification of innate immune pathways implicated in virus-induced autoimmune diabetes. Clin Immunol. 2009;132:103–15.CrossRefPubMed
7.
Londono P, Komura A, Hara N, Zipris D. Brief dexamethasone treatment during acute infection prevents virus-induced autoimmune diabetes. Clin Immunol. 2010;135:401–11.CrossRefPubMed
8.
Eizirik DL, Mandrup-Poulsen T. A choice of death—the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia. 2001;44:2115–33.CrossRefPubMed
9.
Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia. 1996;39:1005–29.CrossRefPubMed
10.
Pickersgill LMS, Mandrup-Poulsen TR. The anti-interleukin-1 in type 1 diabetes action trial—background and rationale. Diabetes Metab Res Rev. 2009;25:321–4.CrossRefPubMed
11.
Van Belle TL, Pagni PP, Liao J, Sachithanantham S, Dave A, Bel Hani A, et al. Beta-cell-specific production of IL6 in conjunction with a mainly intracellular but not mainly surface viral protein causes diabetes. J Autoimmun. 2014;55:24–32.CrossRefPubMed
12.
Agrawal RP, Jain S, Shah S, Chopra A, Agarwal V. Effect of camel milk on glycemic control and insulin requirement in patients with type 1 diabetes: 2-years randomized controlled trial. Eur J Clin Nutr. 2011;65:1048–52.CrossRefPubMed
13.
Khaskheli M, Arian MA, Chaudhry S, Soomro AH, Qureshi TA. Physico-chemical quality of camel milk. J Agric Soc Sci. 2005;2:164–6.
14.
Korish AA. The antidiabetic action of camel milk in experimental type 2 diabetes mellitus: an overview of the changes in incretin hormones, insulin resistance, and inflammatory cytokines. Horm Metab Res. 2014;46(6):404–11.CrossRefPubMed
15.
Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes. 2005;54(8):2460–70.CrossRef
16.
Malik A, Al-Senaidy A, Skrzypczak-Jankun E, Jankun J. A study of the anti-diabetic agents of camel milk. Int J Mol Med. 2012;30:585–92.CrossRefPubMed
17.
Metz-Boutique MH, Jolles J, Mazurier J, Schoentgen F, Legrand D, Spik G, Montreuil J, Jolles P. Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. Eur J Biochem. 1984;145:659–76.CrossRef
18.
Konuspayeva G, Faye B, Loiseau G, Levieux D. Lactoferrin and immunoglobulin content in camel’s milk (Camelus bactrianus, Camelus dromedarius, and hybrids) from Kazakhstan. J Dairy Sci. 2007;90:38–46.CrossRefPubMed
19.
20.
Agrawal RP, Dogra R, Mohta N, Tiwari R, Singhal S, Sultania S. Beneficial effect of camel milk in diabetic nephropathy. Acta Biomed. 2009;80(2):131–4.PubMed
21.
Yamaguchi M, Matsuura M, Kobayashi K, Sasaki H, Yajima T, Kuwata T. Lactoferrin protects against the development of hepatitis caused by sensitization of kupffer cells by lipopolysaccharide. Clin Diagn Lab Immunol. 2001;8:1234–9.PubMedPubMedCentral
22.
Haversen L, Ohlsson BG, Hahn-Zoric M, Hanson LA, Mattsby-Baltzer I. Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa b. Cell Immunol. 2002;220:83–95.CrossRefPubMed
23.
Kawakami H, Lönnerdal B. Isolation and function of a receptor for human lactoferrin in human fetal intestinal brush border membranes. Am J Physiol. 1991;261:G841–6.PubMed
24.
Kitagawa H, Yoshizawa Y, Yokoyama T, Takeuchi T, Talukder MJ, Shimizu H, Ando K, Harada E. Persorption of bovine lactoferrin from the intestinal lumen into the systemic circulation via the portal vein and the mesenteric lymphatics in growing pigs. J Vet Med Sci. 2003;65(5):567–72.CrossRefPubMed
25.
Roy A, Srivastava M, Saqib U, et al. Potential therapeutic targets for inflammation in toll-like receptor 4 (TLR4)-mediated signaling pathways. Int Immunopharmacol. 2016;40:79–89.CrossRefPubMed
26.
27.
Ahmad R, Al-Mass A, Atizado V, et al. Elevated expression of the toll like receptors 2 and 4 in obese individuals: its significance for obesity-induced inflammation. J Inflamm. 2012;9:48.CrossRef
28.
Rodgers JT, Puigserver P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc Natl Acad Sci USA. 2007;104:12861–6.CrossRefPubMed
29.
Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009;9:327–38.CrossRefPubMedPubMedCentral
30.
Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes. 2005;54(8):2460–70.CrossRef
31.
Gupta D, Kono T, Evans-Molina C. The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. Diabetes Obes Metab. 2010;12(12):1036–47.CrossRefPubMedPubMedCentral
32.
Bonner-Weir S. Life and death of the pancreatic beta cells. Trends Endocrinol Metab. 2000;11:375–8.CrossRefPubMed
33.
Kushner JA, Ciemerych MA, Sicinska E, Wartschow LM, Teta M, Long SY, Sicinski P, White MF. Cyclins D2 and D1 are essential for postnatal pancreatic beta-cell growth. Mol Cell Biol. 2005;25:3752–62.CrossRefPubMedPubMedCentral
34.
Boraschi D, Dinarello CA. IL-18 in autoimmunity: review. Eur Cytokine Netw. 2006;17:224–52.PubMed
35.
Jessen BA, Stevens GJ. Expression profiling during adipocyte differentiation of 3T3-L1 fibroblasts. Gene. 2002;299:95–100.CrossRefPubMed
36.
Cowland JB, Muta T, Borregaard N. IL-1beta-specific up-regulation of neutrophil gelatinase-associated lipocalin is controlled by IkappaB-zeta. J Immunol. 2006;176:5559–66.CrossRefPubMed
37.
Zannolli R, Rebeggiani A, Chiarelli F, Morgese G. Hyperinsulinism as a marker in obese children. Am J Dis Child. 1993;147:837–41.PubMed
38.
Maruhama Y, Abe R. A familial form of obesity without hyperinsulinism at the outset. Diabetes. 1981;30:14–8.CrossRefPubMed
39.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.CrossRefPubMed
40.
Agrawal RP, Tantia P, Jain S, Agrawal R, Agrawal V. Camel milk: a possible boon for type 1 diabetic patients. Cell Mol Biol. 2013;59(1):99–107.PubMed
41.
Agrawal RP, Dogra R, Mohta N, Tiwari R, Singhal S, Sultania S. Beneficial effect of camel milk in diabetic nephropathy. Acta Biomed. 2009;80(2):131–4.PubMed
42.
Fuentes-Antrás J, Ioan AM, Tuñón J, Egido J, Lorenzo O. Activation of toll-like receptors and inflammasome complexes in the diabetic cardiomyopathy-associated inflammation. Int J Endocrinol. 2014;2014:847827.CrossRefPubMedPubMedCentral
43.
Gahr M, Speer C, Damerau B, Sawatzki G. Influence of lactoferrin on the function of human polymorphonuclear leukocytes and monocytes. J Leukoc Biol. 1991;49:427–33.CrossRefPubMed
44.
Farnaud S, Evans RW. Lactoferrin—a multifunctional protein with antimicrobial properties. Mol Immunol. 2003;40:395–405.CrossRefPubMed
45.
Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, ten Cate JW, van Deventer SJ. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med. 1996;184:1601–8.CrossRefPubMed
46.
Arab HH, Salama SA, Abdelghany TM, et al. Camel milk attenuates rheumatoid arthritis via inhibition of mitogen activated protein kinase pathway. Cell Physiol Biochem. 2017;43:540–52.CrossRefPubMed
47.
El-Desouky MA, Osman S, Shams Eldin NS, Emaraa I. Arginase enzyme activity and lactoferrin protein concentration in Egyptian diabetic patients. Int J Adv Res. 2017;5(1):1518–23.CrossRef
48.
Wang C, Li C, Peng H, Ye Z, Zhang J, Liu X, Lou T. Activation of the Nrf2-ARE pathway attenuates hyperglycemia-mediated injuries in mouse podocytes. Cell Physiol Biochem. 2014;34:891–902.CrossRefPubMed
49.
Kim HJ, Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol. 2010;298:F662–71.CrossRefPubMed
50.
Matsebatlela TM, Anderson AL, Gallicchio VS, Elford H, Rice CD. 3,4-Dihydroxy-benzohydroxamic acid (Didox) suppresses pro-inflammatory profiles and oxidative stress in TLR4-activated RAW264.7 murine macrophages. Chem Biol Interact. 2015;233:95-105.CrossRefPubMedPubMedCentral
51.
Baveye S, Elass E, Mazurier J, Spik G, Legrand D. Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin Chem Lab Med. 1999;37:281–6.CrossRefPubMed
52.
Gu J, Su S, Guo J, Zhu Y, Zhao M, Duan JA. Anti-inflammatory and anti-apoptotic effects of the combination of Ligusticum chuanxiong and Radix Paeoniae against focal cerebral ischemia via TLR4/MyD88/MAPK/NF-κB signaling pathway in MCAO rats. J Pharm Pharmacol. 2017;70(2):268–77.CrossRefPubMed
53.
Rasheed N, Alghasham A, Rasheed Z. Lactoferrin from Camelus dromedarius inhibits nuclear transcription factor-kappa B activation, cyclooxygenase-2 expression and prostaglandin E2 production in stimulated human chondrocytes. Pharmacogn Res. 2016;8:135–41.CrossRef
54.
Pickersgill LMS, Mandrup-Poulsen TR. The anti-interleukin-1 in type 1 diabetes action trial-background and rationale. Diabetes Metab Res Rev. 2009;25:321–4.CrossRefPubMed
55.
Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress and lipid peroxidation in patients with hyperglycaemic crisis. Diabetes. 2004;53:2079–86.CrossRef
56.
Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther. 2006;8:2.CrossRef
57.
Kimura A, Naka T, Kishimoto T. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci USA. 2007;104:12099–104.CrossRefPubMed
58.
Wasmuth HE, Kunz D, Graf J, Stanzel S, Purucker EA, Koch A, et al. Hyperglycaemia at admission to the intensive care unit is associated with elevated serum concentrations of interleukin-6 and reduced ex vivo secretion of tumor necrosis factor-a. Crit Care Med. 2004;32:1109–14.CrossRefPubMed
59.
Alkanani AK, Rewers M, Dong F, Waugh K, Gottlieb PA, Zipris D. Dysregulated Toll-Like receptor-induced interleukin-1β and interleukin-6 responses in subjects at risk for the development of type 1 diabetes. Diabetes. 2012;61:2525–33.CrossRefPubMedPubMedCentral
60.
Jun-Ichi T, Hajime N, Katsuaki T, Masahiko I, Tadashi U, Atsushi N, Makoto N, Shinobu S, Toshifumi S, Hisahiko S. Lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. Am J Physiol Gastrointest Liver Physiol. 2002;283:G187–95.CrossRef
61.
Beata N, Marcin F, Tomasz K, Maja K, Micha Z. Lactoferrin inhibits the growth of nasal polypfibroblasts. Pharmacol Rep. 2010;62:1139–47.CrossRef
62.
Yagi M, Suzuki N, Takayama T, Arisue M, Kodama T, Yoda Y, et al. Lactoferrin suppress the adipogenic differentiation of MC3T3-G2/PA6 cells. J Oral Sci. 2008;50(4):419–25.CrossRefPubMed
63.
Moreno-Navarrete JM, Ortega FJ, Ricart W, Fernandez-Real JM. Lactoferrin increases (172Thr)AMPK phosphorylation and insulin-induced (p473Ser)AKT while impairing adipocyte differentiation. Int J obes. 2009;33(9):991–1000.CrossRef
64.
Zhang J, Wu Y, Zhang Y, LeRoith D, Bernlohr DA, Chen X. The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Mol Endocrinol. 2008;22:1416–26.CrossRefPubMedPubMedCentral
65.
Yan QW, Yang Q, Mody N, Graham TE, Hsu CH, Xu Z, et al. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes. 2007;56:2533–40.CrossRefPubMed
66.
Meena S, Rajput YS, Pandey AK, Sharma R, Singh R. Camel milk ameliorates hyperglycemia and oxidative damage in type-1 diabetic experimental rats. J Dairy Res. 2016;83:412–9.CrossRefPubMed
67.
Hosooka T, Ogawa W. A novel role for the cell cycle regulatory complex cyclin D1–CDK4 in gluconeogenesis. J Diabetes Investig. 2016;7(1):27–8.CrossRefPubMed
68.
Bhalla K, Liu WJ, Thompson K, et al. Cyclin D1 represses gluconeogenesis via inhibition of the transcriptional coactivator PGC1α. Diabetes. 2014;63:3266–78.CrossRefPubMedPubMedCentral
69.
Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes. 2005;54(8):2460–70.CrossRef
70.
Gupta D, Kono T, Evans-Molina C. The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. Diabetes Obes Metab. 2010;12(12):1036–47.CrossRefPubMedPubMedCentral
71.
Kushner JA, Ciemerych MA, Sicinska E, Wartschow LM, Teta M, Long SY, Sicinski P, White MF. Cyclins D2 and D1 are essential for postnatal pancreatic beta-cell growth. Mol Cell Biol. 2005;25:3752–62.CrossRefPubMedPubMedCentral
72.
Moreno-Navarrete JM, Ortega FJ, Bassols J, Castro A, Ricart W, Fernández-Real JM. Association of circulating lactoferrin concentration and 2 nonsynonymous LTF gene polymorphisms with dyslipidemia in men depends on glucose-tolerance status. Clin Chem. 2008;54(2):301–9.CrossRefPubMed
73.
Artym J. A remedy against obesity? The role of lactoferrin in the metabolism of glucose and lipids. Postepy Hig Med Dosw. 2012;66:937–53.CrossRef
74.
Moastafa TM, El-Sissy AE, El-Saeed GK, Koura MS. Study on the therapeutic benefit on lactoferrin in patients with colorectal cancer receiving chemotherapy. Int Sch Res Not. 2014;28(2014):184278.
Metadata
Title
Antidiabetic efficacy of lactoferrin in type 2 diabetic pediatrics; controlling impact on PPAR-γ, SIRT-1, and TLR4 downstream signaling pathway
Authors
Waleed A. Mohamed
Mona F. Schaalan
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2018
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-018-0390-x

Other articles of this Issue 1/2018

Diabetology & Metabolic Syndrome 1/2018 Go to the issue

Research

Population attributable fractions for Type 2 diabetes: an examination of multiple risk factors including symptoms of depression and anxiety

Research

Exploring structural barriers to diabetes self-management in Alberta First Nations communities

Research

Prevalence and predictors of metabolic syndrome among people living with human immunodeficiency virus (PLWHIV)

Research

Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance

Research

The effectiveness of stress management training on blood glucose control in patients with type 2 diabetes

Research

Associations of serum calcium levels and dietary calcium intake with incident type 2 diabetes over 10 years: the Korean Genome and Epidemiology Study (KoGES)

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits